Literature DB >> 10463481

Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas.

K J Busam1, L K Tan, S R Granter, S Kohler, J Junkins-Hopkins, M Berwick, P P Rosen.   

Abstract

The distinction between primary sweat gland carcinomas and metastatic breast carcinoma to the skin is sometimes difficult. In an effort to improve this discrimination, we compared the immunohistochemical staining pattern of 42 primary sweat gland carcinomas (SGCs) with 30 metastases from breast carcinoma (BC) to the skin, 125 primary BCs, and 30 noncutaneous metastases from BCs. The antibodies used were against the receptors for epidermal growth factor (EGF-R), estrogen receptor (ER), and progesterone receptor (PR). The frequencies of positive staining were as follows for EGF-R: 34 (81%) of 42 SGCs, 5 (17%) of 30 BCs metastatic to skin, 28 (22%) of 125 primary BCs, and 6 (20%) of 30 noncutaneous BC metastases. For ER, the frequencies were 9 (21%) of 42 SGCs and 10 (33%) of 30 BCs metastatic to skin. The frequencies for PR were 8 (19%) of 42 SGCs and 8 (27%) of 30 BCs metastatic to skin. These results suggest that expression of EGF-R may be diagnostically helpful, because it is strongly associated with SGCs when compared with metastatic BCs (P < .0001). This association is also present when ductal eccrine and apocrine types of SGC, which are the histologic subtypes of SGC most difficult to distinguish from metastatic BC, are separately analyzed (P < .001). The frequencies of expression of ER and PR in SGCs and BCs metastatic to skin were not significantly different.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463481

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Sweat gland progenitors in development, homeostasis, and wound repair.

Authors:  Catherine Lu; Elaine Fuchs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

Review 2.  Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands.

Authors:  Nidal A Obaidat; Khaled O Alsaad; Danny Ghazarian
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

Review 3.  Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature.

Authors:  K N MacNeill; R H Riddell; D Ghazarian
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

4.  [Atypical course of an apocrine sweat gland carcinoma of the axilla : A very rare malignant tumor and its interdisciplinary treatment].

Authors:  U Wauer; D Lorenz; R Sellei; E Zoga; S Braun
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

5.  Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.

Authors:  Long P Le; Dora Dias-Santagata; Amanda C Pawlak; Arjola K Cosper; Anh Thu Nguyen; M Angelica Selim; April Deng; Nora K Horick; A John Iafrate; Martin C Mihm; Mai P Hoang
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

6.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

7.  Eccrine carcinoma : a rare cutaneous neoplasm.

Authors:  Karima Idrissi Serhrouchni; Taoufiq Harmouch; Laila Chbani; Hind El Fatemi; Mohammed Sekal; Nawal Hammas; Meriem Soughi; Loubna Benchat; Afaf Amarti
Journal:  Diagn Pathol       Date:  2013-02-04       Impact factor: 2.644

Review 8.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.